- Featured Product
- KD/KO Validated
Alpha Galactosidase A Monoclonal antibody, PBS Only
Alpha Galactosidase A Monoclonal Antibody for WB, IHC, IF/ICC, Indirect ELISA
Host / Isotype
Mouse / IgG2a
Reactivity
human
Applications
WB, IHC, IF/ICC, Indirect ELISA
Conjugate
Unconjugated
CloneNo.
2B2C5
Cat no : 66121-1-PBS
Synonyms
Validation Data Gallery
Tested Applications
Recommended dilution
Application | Dilution |
---|---|
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. |
Product Information
66121-1-PBS targets Alpha Galactosidase A in WB, IHC, IF/ICC, Indirect ELISA applications and shows reactivity with human samples.
Tested Reactivity | human |
Host / Isotype | Mouse / IgG2a |
Class | Monoclonal |
Type | Antibody |
Immunogen | Alpha Galactosidase A fusion protein Ag7505 相同性解析による交差性が予測される生物種 |
Full Name | galactosidase, alpha |
Calculated molecular weight | 49 kDa |
Observed molecular weight | 49 kDa |
GenBank accession number | BC002689 |
Gene symbol | GLA |
Gene ID (NCBI) | 2717 |
RRID | AB_2881520 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A purification |
Storage Buffer | PBS Only |
Storage Conditions | Store at -80°C. |
Background Information
GLA, also named as Melibiase and Alpha-galactosidase A, belongs to the glycosyl hydrolase 27 family. It hydrolyzes terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy (ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.